Similar articles

• Combined use of Orgaran and Reopro during coronary angioplasty in patients unable to receive heparin.

  Cantor WJ, Leblanc K, Garvey B, Watson KR, Rasymas A, Strauss BH. Cantor WJ, et al. Catheter Cardiovasc Interv. 1999 Mar;46(3):352-5. doi: 10.1002/(SICI)1522-726X(199903)46:3<352::AID-CCD21>3.0.CO;2-7. Catheter Cardiovasc Interv. 1999. PMID: 10348139
• Orgaran during rotational atherectomy in the setting of heparin-induced thrombocytopenia.

  Hale LP, Smith K, Braden GA, Owen J. Hale LP, et al. Cathet Cardiovasc Diagn. 1998 Nov;45(3):318-22. doi: 10.1002/(sici)1097-0304(199811)45:3<318::aid-ccd23>3.0.co;2-2. Cathet Cardiovasc Diagn. 1998. PMID: 9829897
• Treatment of heparin-induced thrombocytopenia.

  Peters FP. Peters FP. J Thorac Cardiovasc Surg. 1997 Sep;114(3):517-8. doi: 10.1016/S0022-5223(97)70219-8. J Thorac Cardiovasc Surg. 1997. PMID: 9305220 No abstract available.
• Heparinoid anticoagulation and topical fibrin sealant in heparin-induced thrombocytopenia.

  Jackson MR, Danby CA, Alving BM. Jackson MR, et al. Ann Thorac Surg. 1997 Dec;64(6):1815-7. doi: 10.1016/s0003-4975(97)01065-5. Ann Thorac Surg. 1997. PMID: 9436582 Review.
• Vascular drugs in the new millennium.

  Frangos SG, Chen AH, Sumpio B. Frangos SG, et al. J Am Coll Surg. 2000 Jul;191(1):76-92. doi: 10.1016/s1072-7515(00)00292-1. J Am Coll Surg. 2000. PMID: 10898187 Review. No abstract available.